Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$240B
P/E ratio
~33×
Div yield
~2.1%
EPS (TTM)
~$4.40
Profit margin
~13%
Rev. growth
+8%
Revenue
~$59B
R&D spend
~$14B
In plain English
AstraZeneca is a UK-headquartered global biopharma whose growth engine is oncology — blockbuster cancer medicines like Tagrisso, Imfinzi and the Daiichi Sankyo-partnered antibody-drug conjugates Enhertu and Datroway — alongside big cardiovascular/renal/metabolic and respiratory franchises and, since the ~$39B Alexion takeover, a rare-disease business. It runs a pipeline-driven model: heavy R&D and a string of bolt-on biotech acquisitions feed a portfolio sold to payers, hospitals and patients worldwide.
In simple terms
What AstraZeneca really sells
AstraZeneca is a UK-headquartered global biopharma whose growth engine is oncology — blockbuster cancer medicines like Tagrisso, Imfinzi and the Daiichi Sankyo-partnered antibody-drug conjugates Enhertu and Datroway — alongside big cardiovascular/renal/metabolic and respiratory franchises and, since the ~$39B Alexion takeover, a rare-disease business. It runs a pipeline-driven model: heavy R&D and a string of bolt-on biotech acquisitions feed a portfolio sold to payers, hospitals and patients worldwide.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.